High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

Abstract Background MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype of sporadic RCC that is predominantly seen in young patients and can...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Martin Lang, Laura S. Schmidt, Kelli M. Wilson, Christopher J. Ricketts, Carole Sourbier, Cathy D. Vocke, Darmood Wei, Daniel R. Crooks, Youfeng Yang, Benjamin K. Gibbs, Xiaohu Zhang, Carleen Klumpp-Thomas, Lu Chen, Rajarshi Guha, Marc Ferrer, Crystal McKnight, Zina Itkin, Darawalee Wangsa, Danny Wangsa, Amy James, Simone Difilippantonio, Baktir Karim, Francisco Morís, Thomas Ried, Maria J. Merino, Ramaprasad Srinivasan, Craig J. Thomas, W. Marston Linehan
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2023-04-01
Sarja:	Journal of Experimental & Clinical Cancer Research
Aiheet:	MiT family translocation RCC TFE3-RCC TFE3-fusion GPNMB RCC therapy NVP-BGT226
Linkit:	https://doi.org/10.1186/s13046-023-02667-4
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!